Gene Therapy Restores Hearing in Patients with Genetic Deafness—Clinical Trial Shows Rapid Improvement After Single Injection
Key Takeaways
- ▸Single-injection gene therapy successfully restored hearing in all ten trial participants with OTOF-related genetic deafness, with effects appearing within one month
- ▸Children showed the most dramatic improvements, with one seven-year-old regaining near-full hearing and achieving everyday conversation ability within four months
- ▸The therapy was safe and well-tolerated with minimal adverse effects, establishing a foundation for treating other genetic forms of deafness
Summary
Researchers at Karolinska Institutet, in collaboration with hospitals and universities in China, have demonstrated that gene therapy can significantly restore hearing in patients with congenital deafness caused by OTOF gene mutations. In a clinical trial involving ten patients aged 1 to 24, a single injection of a synthetic adeno-associated virus (AAV) carrying a functional OTOF gene was delivered directly into the inner ear via the round window membrane. Most patients began regaining hearing within one month, with all participants showing clear improvement by six months—average sound detection improved from 106 decibels to 52 decibels. The therapy proved safe and well-tolerated, with the most common side effect being a temporary decrease in neutrophils. The findings, published in Nature Medicine, represent a major breakthrough in genetic treatment of hearing loss, particularly for children aged 5–8 who showed the most dramatic responses. Researchers are now expanding the approach to treat other genetic forms of deafness caused by mutations in genes like GJB2 and TMC1.
- Researchers plan to expand treatment to additional deafness-causing genes (GJB2, TMC1), with animal studies already showing promising results
Editorial Opinion
This gene therapy breakthrough represents a watershed moment in treating genetic hearing loss, transforming what was once an untreatable condition into a reversible one with a single intervention. The rapid and durable results—especially in younger patients—demonstrate the power of precision medicine when targeting specific genetic causes. While the current approach addresses only OTOF mutations (representing a minority of genetic deafness cases), the clear pathway to treating more common deafness genes like GJB2 and TMC1 suggests this could become a standard treatment modality within years, potentially benefiting millions globally.
